Skip to main content
Erschienen in: Rheumatology International 2/2011

01.02.2011 | Case Report

A case with rheumatoid arthritis and systemic reactive AA amyloidosis showing rapid regression of amyloid deposition on gastroduodenal mucosa after a combined therapy of corticosteroid and etanercept

verfasst von: Wataru Ishii, Dai Kishida, Ayako Suzuki, Yasuhiro Shimojima, Masayuki Matsuda, Yoshinobu Hoshii, Shu-ichi Ikeda

Erschienen in: Rheumatology International | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Systemic reactive amyloid A (AA) amyloidosis is one of the critical complications associated with rheumatoid arthritis (RA). Recently, there are several useful reports of anti-tumor necrosis factor therapy for RA-related systemic reactive AA amyloidosis patients. However, the time-kinetic transition between effective anti-inflammatory therapies and regression of AA amyloid deposits remains uncertain. Here, we report a RA patient with systemic reactive AA amyloidosis who was successfully treated with prednisolone and etanercept, showing marked regression of gastroduodenal mucosal amyloid deposits within only 4 months. This is the first case report of RA-related systemic reactive AA amyloidosis histopathologically demonstrating rapid regression of amyloid deposits on gastroduodenal mucosa after adequate suppression of the underlying inflammatory condition.
Literatur
1.
Zurück zum Zitat Husby G, Marhaug G, Dowton B, Sletten K, Sipe JD (1994) Serum amyloid A (SAA): biochemistry, genetics and the pathogenesis of AA amyloidosis. Amyloid 1:119–137CrossRef Husby G, Marhaug G, Dowton B, Sletten K, Sipe JD (1994) Serum amyloid A (SAA): biochemistry, genetics and the pathogenesis of AA amyloidosis. Amyloid 1:119–137CrossRef
2.
Zurück zum Zitat Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P (2007) New therapies for treatment of rheumatoid arthritis. Lancet 370:1861–1874CrossRefPubMed Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P (2007) New therapies for treatment of rheumatoid arthritis. Lancet 370:1861–1874CrossRefPubMed
3.
Zurück zum Zitat Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D (2002) Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum 46:2571–2573CrossRefPubMed Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D (2002) Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum 46:2571–2573CrossRefPubMed
4.
Zurück zum Zitat Gottenberg JE, Merle-Vincent F, Bentaberry F, Allanore Y, Berenbaum F, Fautrel B et al (2003) Anti-tumor necrosis factor α therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a follow-up report of tolerability and efficacy. Arthritis Rheum 48:2019–2024CrossRefPubMed Gottenberg JE, Merle-Vincent F, Bentaberry F, Allanore Y, Berenbaum F, Fautrel B et al (2003) Anti-tumor necrosis factor α therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a follow-up report of tolerability and efficacy. Arthritis Rheum 48:2019–2024CrossRefPubMed
5.
Zurück zum Zitat Fernández-Nebro A, Tomero E, Ortiz-Santamaría V, Castro MC, Olivé A, de Haro M et al (2005) Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med 118:552–556CrossRefPubMed Fernández-Nebro A, Tomero E, Ortiz-Santamaría V, Castro MC, Olivé A, de Haro M et al (2005) Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med 118:552–556CrossRefPubMed
6.
Zurück zum Zitat Okuda Y, Takasugi K (2006) Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum 54:2997–3000CrossRefPubMed Okuda Y, Takasugi K (2006) Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum 54:2997–3000CrossRefPubMed
7.
Zurück zum Zitat Kuroda T, Otaki Y, Sato H, Fujimura T, Nakatsue T, Murakami S et al (2008) A case of AA amyloidosis associated with rheumatoid arthritis effectively treated with infliximab. Rheumatol Int 28:1155–1159CrossRefPubMed Kuroda T, Otaki Y, Sato H, Fujimura T, Nakatsue T, Murakami S et al (2008) A case of AA amyloidosis associated with rheumatoid arthritis effectively treated with infliximab. Rheumatol Int 28:1155–1159CrossRefPubMed
8.
Zurück zum Zitat Hoshii Y, Kiyama M, Cui D, Kawano H, Ishihara T (2006) Immunohistochemical study of immunoglobulin light chain amyloidosis with antibodies to the immunoglobulin light chain variable region. Pathol Int 56:324–330CrossRefPubMed Hoshii Y, Kiyama M, Cui D, Kawano H, Ishihara T (2006) Immunohistochemical study of immunoglobulin light chain amyloidosis with antibodies to the immunoglobulin light chain variable region. Pathol Int 56:324–330CrossRefPubMed
9.
Zurück zum Zitat Ishii W, Matsuda M, Nakamura A, Nakamura N, Suzuki A, Ikeda S (2003) Abdominal fat aspiration biopsy and genotyping of serum amyloid A contribute to early diagnosis of reactive AA amyloidosis secondary to rheumatoid arthritis. Intern Med 42:800–805CrossRefPubMed Ishii W, Matsuda M, Nakamura A, Nakamura N, Suzuki A, Ikeda S (2003) Abdominal fat aspiration biopsy and genotyping of serum amyloid A contribute to early diagnosis of reactive AA amyloidosis secondary to rheumatoid arthritis. Intern Med 42:800–805CrossRefPubMed
10.
Zurück zum Zitat Kuroda T, Tanabe N, Harada T, Murakami S, Hasegawa H, Sakatsume M et al (2006) Long-term mortality outcome in patients with reactive amyloidosis associated with rheumatoid arthritis. Clin Rheumatol 25:498–505CrossRefPubMed Kuroda T, Tanabe N, Harada T, Murakami S, Hasegawa H, Sakatsume M et al (2006) Long-term mortality outcome in patients with reactive amyloidosis associated with rheumatoid arthritis. Clin Rheumatol 25:498–505CrossRefPubMed
11.
Zurück zum Zitat Okuda Y, Takasugi K, Oyama T, Oyama H, Nanba S, Miyamoto T (1997) Intractable diarrhoea associated with secondary amyloidosis in rheumatoid arthritis. Ann Rheum Dis 56:535–541CrossRefPubMed Okuda Y, Takasugi K, Oyama T, Oyama H, Nanba S, Miyamoto T (1997) Intractable diarrhoea associated with secondary amyloidosis in rheumatoid arthritis. Ann Rheum Dis 56:535–541CrossRefPubMed
12.
Zurück zum Zitat Moriguchi M, Terai C, Koseki Y, Uesato M, Nakajima A, Inada S et al (1999) Influence of genotypes at SAA1 and SAA2 loci on the development and the length of latent period of secondary AA-amyloidosis in patients with rheumatoid arthritis. Hum Genet 105:360–366CrossRefPubMed Moriguchi M, Terai C, Koseki Y, Uesato M, Nakajima A, Inada S et al (1999) Influence of genotypes at SAA1 and SAA2 loci on the development and the length of latent period of secondary AA-amyloidosis in patients with rheumatoid arthritis. Hum Genet 105:360–366CrossRefPubMed
13.
Zurück zum Zitat Moriguchi M, Terai C, Koseki Y, Kaneko H, Uesato M, Nishikawa T et al (2001) Genotypes at SAA1 locus correlate with the clinical severity of AA-amyloidosis. Amyloid 8:115–120PubMed Moriguchi M, Terai C, Koseki Y, Kaneko H, Uesato M, Nishikawa T et al (2001) Genotypes at SAA1 locus correlate with the clinical severity of AA-amyloidosis. Amyloid 8:115–120PubMed
14.
Zurück zum Zitat Lachmann HJ, Goodman HJB, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD et al (2007) Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356:2361–2371CrossRefPubMed Lachmann HJ, Goodman HJB, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD et al (2007) Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356:2361–2371CrossRefPubMed
15.
Zurück zum Zitat Fushimi T, Takahashi Y, Kashima Y, Fukushima K, Ishii W, Kaneko K et al (2005) Severe protein losing enteropathy with intractable diarrhea due to systemic AA amyloidosis, successfully treated with corticosteroid and octreotide. Amyloid 12:48–53CrossRefPubMed Fushimi T, Takahashi Y, Kashima Y, Fukushima K, Ishii W, Kaneko K et al (2005) Severe protein losing enteropathy with intractable diarrhea due to systemic AA amyloidosis, successfully treated with corticosteroid and octreotide. Amyloid 12:48–53CrossRefPubMed
16.
Zurück zum Zitat Tsuchiya A, Yazaki M, Kametani F, Takei Y, Ikeda S (2008) Marked regression of abdominal fat amyloid in patients with familial amyloid polyneuropathy during long-term follow-up after liver transplantation. Liver Transpl 14:563–570CrossRefPubMed Tsuchiya A, Yazaki M, Kametani F, Takei Y, Ikeda S (2008) Marked regression of abdominal fat amyloid in patients with familial amyloid polyneuropathy during long-term follow-up after liver transplantation. Liver Transpl 14:563–570CrossRefPubMed
17.
Zurück zum Zitat Richter GW (1954) The resorption of amyloid under experimental conditions. Am J Pathol 30:239–262PubMed Richter GW (1954) The resorption of amyloid under experimental conditions. Am J Pathol 30:239–262PubMed
Metadaten
Titel
A case with rheumatoid arthritis and systemic reactive AA amyloidosis showing rapid regression of amyloid deposition on gastroduodenal mucosa after a combined therapy of corticosteroid and etanercept
verfasst von
Wataru Ishii
Dai Kishida
Ayako Suzuki
Yasuhiro Shimojima
Masayuki Matsuda
Yoshinobu Hoshii
Shu-ichi Ikeda
Publikationsdatum
01.02.2011
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 2/2011
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-1205-z

Weitere Artikel der Ausgabe 2/2011

Rheumatology International 2/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.